Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2014', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview 9
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis 10
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies 11
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes 13
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies 17
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes 18
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development 19
Johnson & Johnson 19
Takeda Pharmaceutical Company Limited 20
Eisai Co., Ltd. 21
Ono Pharmaceutical Co., Ltd. 22
Wockhardt Limited 23
Shire Plc 24
Yuhan Corporation 25
Torrent Pharmaceuticals Limited 26
Ahn-Gook Pharmaceutical Co., Ltd. 27
Ironwood Pharmaceuticals, Inc. 28
Rottapharm SpA 29
aRigen Pharmaceuticals, Inc. 30
Cempra, Inc. 31
Vecta Ltd. 32
RaQualia Pharma Inc. 33
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
vonoprazan - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pantoprazole - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(esomeprazole magnesium + levosulpiride) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
omeprazole - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
itriglumide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RQ-00000004 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SSP-002358 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
YH-4808 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Polyclonal Antibody Stimulator - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
IW-3718 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
esomeprazole magnesium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
tenatoprazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
E-3710 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ARH-1029 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
RQ-00000010 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ONO-8539 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
RQ-00000774 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
JNJ-26070109 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Inhibit Proton Pump for Gastrointestinal Disorders - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Recent Pipeline Updates 67
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects 71
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products 72
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones 73
Featured News & Press Releases 73
Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease 73
Dec 23, 2013: Federal Appeals Court Ruling Affirms Amneal's Green Light to Market New Esomeprazole Strontium Delayed-Release Capsules 73
Dec 19, 2013: Dexlansoprazole, a New Dual-Delayed Release Technology for the Treatment Of Reflux Disease, Accepted for National Approvals Within the European Union 74
Dec 17, 2013: Amneal Launches Esomeprazole Strontium 49.3 mg Delayed-Release Capsules, a Pharmaceutical Alternative to Nexium 75
Dec 17, 2013: AstraZeneca statement in response to reports of a launch of esomeprazole strontium product in the US 75
Nov 08, 2013: Eisai Announces Availability of ACIPHEX Sprinkle for Treatment of GERD in Children Ages 1 to 11 75
Oct 15, 2013: TWi Pharmaceuticals Comments on Dexilant Ruling 76
Mar 27, 2013: Eisai's Aciphex Sprinkle Capsules Obtains FDA Approval For Treatment Of Gastroesophageal Reflux Disease In Children 77
Mar 25, 2013: Takeda Receives Decision From President Of National Tax Tribunal Related To Correction Notice On Transfer Pricing Of Prevacid 77
Dec 10, 2012: Eisai Receives Six-month Pediatric Exclusivity For Proton-pump Inhibitor Aciphex In US 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2014 9
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H2 2014 19
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H2 2014 21
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 22
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H2 2014 23
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Shire Plc, H2 2014 24
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuhan Corporation, H2 2014 25
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 26
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 27
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 28
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Rottapharm SpA, H2 2014 29
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by aRigen Pharmaceuticals, Inc., H2 2014 30
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H2 2014 31
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H2 2014 32
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Assessment by Combination Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics - Recent Pipeline Updates, H2 2014 67
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2014 71
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2014 72